Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals

International Journal of Cancer

Volumn 115, Issue 3, 2005, Pages 437-442

  Chiyo, Masako ^a,b   Shimozato, Osamu ^a   Yu, Ling ^a   Kawamura, Kiyoko ^a   Iizasa, Toshihiko ^b   Fujisawa, Takehiko ^b   Tagawa, Masatoshi ^a  

^a CHIBA CANCER CENTER   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

Dendritic cells; Gene therapy; IFN ; IL 27; Protective immunity

Indexed keywords

GAMMA INTERFERON; GANGLIOSIDE ANTIBODY; GANGLIOTETRAOSYLCERAMIDE; INTERLEUKIN 27; PROTEIN; PROTEIN EBI3; PROTEIN P28; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOLOGY; CANCER SURVIVAL; CELL PROLIFERATION; COLON TUMOR; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EBI3 GENE; FEMALE; GENE; GENETIC TRANSDUCTION; HELPER CELL; LYMPHOCYTE DIFFERENTIATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; NUDE MOUSE; P28 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCID MOUSE; TH1 CELL; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR REJECTION;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; COS CELLS; CYTOTOXICITY TESTS, IMMUNOLOGIC; FEMALE; G(M1) GANGLIOSIDE; GENE THERAPY; GENETIC VECTORS; IMMUNITY, CELLULAR; INJECTIONS, SUBCUTANEOUS; INTERFERON TYPE II; INTERLEUKINS; KILLER CELLS, NATURAL; MICE; MICE, INBRED BALB C; MICE, NUDE; MICE, SCID; RETROVIRIDAE; TRANSDUCTION, GENETIC;

EID: 18644381517     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20848     Document Type: Article

References (21)

1. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996;383:787-93.
2. Tagawa M. Cytokine therapy for cancer. Curr Pharm Des 2000;6:681-99.
3. Roth JA, Cristiano RJ. Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst 1997;89:21-39.
4. Nieuwenhuis EE, Neurath MF, Corazza N, Iijima H, Trgovcich J. Wirtz S, Glickman J. Bailey D, Yoshida M, Galle PR, Kronenberg M, Birkenbach M, et al. Disruption of T helper 2-immune responses in Epstein-Barr virus-induced gene 3-deficient mice. Proc Natl Acad Sci USA 2002;99:16951-6.
5. + T cells. Immunity 2002;16:779-90.
6. Chen Q, Ghilardi N, Wang H, Baker T, Xie MH, Gurney A, Grewal IS, de Sauvage FJ. Development of Th1-type immune responses requires the type I cytokine receptor TCCR. Nature 2000;407:916-20.
7. Takeda A, Hamano S, Yamanaka A, Kanada T, Ishibashi T. Mak TW, Yoshimura A, Yoshida H. Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. J Immunol 2003;170:4886-90.
8. + T cells through Stat1-dependent and -independent mechanisms. Proc Natl Acad Sci USA 2003;100:15047-52.
9. Pflanz S. Hibbert L, Mattson J, Rosales R. Vaisberg E, Bazan JF, Phillips JH, McClanahan TK, de Waal Malefyt R, Kastelein RA. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J Immunol 2004;172:2225-31.
10. Yoshida H, Hamano S, Senaldi G, Covey T, Faggioni R, Mu S, Xia M, Wakeham AC, Nishina H, Potter J, Saris CJ, Mak TW. WSX-1 is required for the initiation of Th1 responses and resistance to L. major infection. Immunity 2001;15:569-78.
11. Villarino A, Hibbert L, Lieberman L, Wilson E, Mak T, Yoshida H, Kastelein RA, Saris C, Hunter CA. The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection. Immunity 2003;19:645-55.
12. Hamano S. Himeno K, Miyazaki Y, Ishii K, Yamanaka A, Takeda A. Zhang M, Hisaeda H, Mak TW, Yoshimura A, Yoshida H. WSX-1 is required for resistance to Trypanosoma cruzi infection by regulation of proinflammatory cytokine production. Immunity 2003;19:657-67.
13. Trinchieri G, Pflanz S, Kastelein RA. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 2003;19:641-4.
14. Duke GM, Hoffman MA, Palmenberg AC. Sequence and structural elements that contribute to efficient encephalomyocarditis virus RNA translation. J Virol 1992;66:1602-9.
15. Tasaki K, Yoshida Y, Maeda T, Miyauchi M, Kawamura K, Takenaga K, Yamamoto H, Kouzu T, Asano T, Ochiai T, Sakiyama S, Tagawa M. Protective immunity is induced in murine colon carcinoma cells by the expression of interleukin-12 or interleukin-18, which activate type 1 helper T cells. Cancer Gene Ther 2000;7:247-54.
16. Ugai S, Shimozato O. Yu L, Wang Y-Q, Kawamura K, Yamamoto H, Yamaguchi T. Saisho H, Sakiyama S, Tagawa M. Transduction of the IL-21 and IL-23 genes in human pancreatic carcinoma cells produces natural killer cell-dependent and -independent antitumor effects. Cancer Gene Ther 2003;10:771-8.
17. Wang Y-Q, Ugai S, Shimozato O, Yu L, Kawamura K, Yamamoto, Yamaguchi T, Saisho H, Tagawa M. Induction of systemic immunity by expression of interleukin-23 in murine colon carcinoma cells. Int J Cancer 2003;105:820-4.
18. Devergne O, Birkenbach M, Kieff E. Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin. Proc Natl Acad Sci USA 1997;94:12041-6.
19. Kato K, Shimozato O, Hoshi K, Wakimoto H, Hamada H, Yagita H, Okumura K. Local production of the p40 subunit of interleukin 12 suppresses T-helper 1-mediated immune responses and prevents allogeneic myoblast rejection. Proc Natl Acad Sci USA 1996;93:9085-9.
20. Yoshida K, Taga T, Saito M, Suematsu S, Kumanogoh A, Tanaka T, Fujiwara H, Hirata M, Yamagami T, Nakahata T, Hirabayashi T, Yoneda Y, et al. Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc Natl Acad Sci USA 1996;93:407-11.
21. Hisada M, Kamiya S. Fujita K, Belladonna ML, Aoki T, Koyanagi Y, Mizuguchi J, Yoshimoto T. Potent antitumor activity of interleukin-27. Cancer Res 2004;64:1152-6.